A Look at Third-Party Oncology Clinical Pathways
In order to improve patient outcomes and reduce variations in oncology care, more and more payers and providers are adopting oncology clinical pathways (OCPs) — treatment protocols that aim to provide the optimal cancer care to patients at the lowest cost, according to a recent MMIT webinar. The share of oncologists exposed to third-party oncology pathways increased from 20% in 2015 to 52% in 2021, with one third of oncologists choosing a provider-focused pathway as of the fourth quarter of 2021. Breast cancer, multiple myeloma and non-small cell lung cancer are among the top therapeutic areas managed by third-party pathways.
SOURCE: “Pathways Utilization Amidst Rising Costs of Oncology Treatments,” MMIT. AIS Health is owned by MMIT.
This infographic was reprinted from AIS Health’s biweekly publication RADAR on Drug Benefits.
Related Posts

McClellan: IRA Price Negotiations May Have Broader Impact Beyond Drugs on List
Read More
FDA Approves First Multiple Sclerosis Biosimilar, Sandoz’s Tyruko
Read More